OKE(SH:688308)2021-04-26 16:00Financial Performance - Operating revenue rose by 80.24% to CNY 225,014,603.24 year-on-year[5] - Net profit attributable to shareholders increased by 177.64% to CNY 46,125,575.46 compared to the same period last year[5] - Basic earnings per share increased by 109.09% to CNY 0.46 per share[5] - Operating profit for Q1 2021 was ¥53,591,028.01, up 182.2% from ¥18,928,182.23 in Q1 2020[21] - Net profit for Q1 2021 was ¥46,125,575.46, representing a 177.5% increase from ¥16,613,444.26 in Q1 2020[23] - Total operating revenue for Q1 2021 reached ¥225,014,603.24, a significant increase of 80.0% compared to ¥124,843,200.22 in Q1 2020[21] Cash Flow - The net cash flow from operating activities decreased by 129.00% to -CNY 37,114,160.96 compared to the previous year[5] - The net cash flow from operating activities was negative at -¥37,114,160.96, a 129.00% increase in cash outflow compared to -¥16,207,269.22 in the same period last year, primarily due to increased cash payments for raw material purchases[13] - The net cash flow from operating activities was -$41.99 million in Q1 2021, worsening from -$10.41 million in Q1 2020[30] Assets and Liabilities - Total assets increased by 3.27% to CNY 1,674,795,413.98 compared to the end of the previous year[5] - Total liabilities amounted to CNY 320,888,848.67, up from CNY 314,442,430.39, which is an increase of about 2.0%[17] - Current assets totaled CNY 1,155,683,622.50, slightly up from CNY 1,133,221,001.63, indicating a growth of about 2.0%[15] - Total liabilities as of the end of Q1 2021 amounted to ¥300,956,653.31, an increase from ¥263,071,096.49 at the end of Q1 2020[21] Shareholder Information - The total number of shareholders reached 4,399 at the end of the reporting period[10] - The top shareholder, Yuan Meihe, holds 18,060,000 shares, accounting for 18.06% of the total shares[10] Research and Development - R&D investment as a percentage of operating income decreased by 1.01 percentage points to 3.86%[5] - Research and development expenses rose by 42.98% to ¥8,686,980.42, indicating a focus on enhancing R&D projects[13] - Research and development expenses for Q1 2021 were ¥8,686,980.42, up 43.2% from ¥6,075,713.00 in Q1 2020[21] Other Income and Expenses - Non-recurring gains and losses totaled CNY 7,387,985.85 for the reporting period[8] - The company reported a significant increase in other income, which rose to ¥5,498,681.45, a 1,140.35% increase from ¥443,316.65, mainly due to increased government subsidies received[13] - The company incurred a financial expense of RMB -1,360,547.36, compared to a financial expense of RMB 598,145.92 in Q1 2020[25] Inventory and Receivables - Accounts receivable increased by 50.04% to ¥183,363,975.51 from ¥122,208,223.01, attributed to expanded sales scale and increased revenue[12] - Inventory increased to CNY 216,493,680.03 from CNY 181,352,115.90, reflecting a growth of approximately 19.4%[15] - The company reported a significant increase in other receivables, rising to CNY 670,028.38 from CNY 383,598.28, a growth of approximately 74.8%[15]